The present invention relates to the preparation and use of improved as well as safe antivenins for clinical management of snake or other poisonous animal bite envenoming. In the present inventions, the immunisation of animals or in-vitro systems are carried out using a set of additional antigens besides venom components. This appropriate antigen mixture along with the venoms produces antivenom antibodies in immunized animals/in vitro systems having reduced anaphylactic potential. Further, in this new product, fractionation, purification process and selection of right components of antibodies, also reduces the anaphylactic reactions. The improved antivenin is having multiple sizes of antibody fraction such as a mixture of Fab and F(ab)2 fragments. The new product composition of different size antibody fractions has a dual effect of neutralizing venom components. One part of the antivenin has low molecular weight and neutralizes the smaller components of the venom causing systemic affects. The other part of the antivenin has high molecular weight and is localized around the bite site, neutralizing higher molecular weight components of the venom. The higher molecular weight components of antivenin also have longer presence in the body of victim till venom is completely cleared or neutralised. The present invention also has excipients to counter any residual anaphylactic reaction and can be administered in field conditions by victim himself or an assistant with the aid of ready to use medical devices or skin patches. The injection device can administer the antivenom by single or multiple route of administration. The multiple route of injection by a single device further adds into dual treatment effect of the antivenin. Further, when the victim reaches the hospital setting, the liquid or the lyophilized formulation of the new innovative product can be safely administered intravenously to continue the treatment with minimum anaphylactic shock.
